RxDoctor Payments Data

Mariali Garcia, MD

Endocrinology, Diabetes & Metabolism · Tucson, AZNPI 1821037573

Payments from drug & device makers

$4,448in general payments, 2019–2025

Across 89 payments — averaging $49.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$1K
  • Abbott$835
  • Lilly USA, LLC$731
  • Bayer$325
  • Amgen$309
  • Mannkind Corporation$235
  • plus $985 from 12 others

What the payments were for

  • Food & beverage$4,436100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,448 in reported general payments places this provider in the 55th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona

Medicare billing

Part B allowed, 2024
$54,709
Medicare patients
110
Services billed
1,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin23$36,148
Soliqua 100-33Insulin Glargine/Lixisenatide18$19,965
MounjaroTirzepatide17$19,130
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$13,666
EliquisApixaban15$12,140
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$3,115
Verapamil Er PmVerapamil Hcl12$2,640
Nano 2nd Gen Pen NeedlePen Needle, Diabetic18$1,687
SynthroidLevothyroxine Sodium14$1,633
Rosuvastatin Calcium85$863
Humulin N KwikpenInsulin Nph Human Isophane14$814
Levothyroxine Sodium106$795
Metformin Hcl74$623
Hydrocortisone12$505
Atorvastatin Calcium50$453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$39$36,14823 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$1,028$19,96518 claims
Lilly USA, LLCMounjaro$731$19,13017 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$28$795106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

Other endocrinology, diabetes & metabolism in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →